SilverScript is helping to reduce costs in 2018 for members who receive treatment for diabetes.
Three long-acting injectable insulin products will be on SilverScript’s 2018 Choice formulary as Tier 2 drugs, representing a nearly 60% savings over 2017 pricing on a 30-day supply when filled at a Choice Preferred Network Pharmacy.
Medicare beneficiaries should speak with their doctors to determine which of the following lower-cost alternatives might be right for them:
- Basaglar® (prefilled pen injectors)
- Levemir® (prefilled pen injectors or vials)
- Tresiba® (prefilled pen injectors)
Please note that these three long-acting insulins will replace Lantus and Toujeo, which will no longer be on the formulary for 2018.
Details about the lower copay insulins:
For more information, contact your Cornerstone representative.